Veristat acquires biometrics CRO Instat Clinical for undisclosed price
24 Oct 2023
Acquisition
Preview
Source: FierceBiotech
Massachusetts-based CRO Veristat continued to expand its bench strength with the acquisition of biometrics trial specialist Instat Clinical Research.
Massachusetts-based CRO Veristat picked up biometrics trial specialist Instat Clinical Research in a move to boost its services and experience.
Instat, which was founded in 2003 and is headquartered in Chatham, New Jersey, is known for its long history of designing clinical trials, and leveraging collected data has led to approvals by regulatory agencies in the U.S., Europe and Asia.
With the deal, the financial details of which were not disclosed, Veristat also picks up an Instat office located in India that complements its presence in Taiwan, the company said in an Oct. 19 press release.
“Instat brings a proven track record having supported over 100 sponsor-led clinical studies, authoring over 150 statistical analysis plans, and participating in over 30 regulatory submissions,” Veristat CEO Patrick Flanagan said in the release.
Back in March 2022, Veristat bought Switzerland-based SFL (Solutions for Life Sciences), which specializes in therapies for orphan diseases and oncology as well as treatments that could combine artificial intelligence, devices and diagnostics.
In the two years before that deal, Veristat acquired two U.K-based companies, specialty contract research firm SQN Clinical and The Clinical Trial Company.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.